Citadel Advisors
SCNI

Citadel Advisors’s Scinai Immunotherapeutics SCNI Stock Holding History

Citadel Advisors’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-34,562
Closed -$24.6K – 14087
2025
Q4 		$24.6K Buy
34,562
+5,932
+21% +$6.76K ﹤0.01% 12284
2025
Q3 		$36.2K Buy
28,630
+17,031
+147% +$29.6K ﹤0.01% 12331
2025
Q2 		$26.6K Buy
+11,599
New +$29.2K ﹤0.01% 12032
2024
Q2 		– Sell
-1,221
Closed -$6.31K – 15258
2024
Q1 		$6.31K Buy
+1,221
New +$6.3K ﹤0.01% 13685
2023
Q1 		– Sell
-1,746
Closed -$51.9K – 15420
2022
Q4 		$51.9K Buy
+1,746
New +$131K ﹤0.01% 12089
2022
Q3 		– Sell
-238
Closed -$28K – 13499
2022
Q2 		$28K Sell
238
-184
-44% -$25.3K ﹤0.01% 12266
2022
Q1 		$70K Buy
+422
New +$61.3K ﹤0.01% 12578
2021
Q4 		– Sell
-181
Closed -$40K – 14650
2021
Q3 		$40K Buy
+181
New +$46.5K ﹤0.01% 13470
2021
Q2 		– Sell
-293
Closed -$111K – 14331
2021
Q1 		$111K Buy
+293
New +$128K ﹤0.01% 12383
2017
Q2 		– Sell
-306
Closed -$177K – 7996
2017
Q1 		$177K Buy
+306
New +$158K ﹤0.01% 6609

Other funds holding SCNI

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's SCNI Position: Q1 2026 in Review

Citadel Advisors sold out of Scinai Immunotherapeutics (SCNI) in Q1 2026, closing a stake of 34,562 shares — an estimated $24.6K sold.

Citadel Advisors first reported a position in SCNI in Q1 2017 and held it in 10 quarters. The position peaked at $177K in Q1 2017. 4 funds tracked by Wall St. Rank hold SCNI as of Q1 2026.

  • Citadel Advisors reported no remaining Scinai Immunotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 34,562 Scinai Immunotherapeutics shares in Q1 2026, an estimated $24.6K.
  • Citadel Advisors first reported a position in Scinai Immunotherapeutics in Q1 2017 and held it in 10 quarters.
  • Citadel Advisors's Scinai Immunotherapeutics position peaked at $177K in Q1 2017.
  • 4 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.